Core Points - Universe Pharmaceuticals INC has received a notice from Nasdaq regarding its delinquency in filing the Annual Report on Form 20-F for the fiscal year ended September 30, 2024, which could lead to delisting from Nasdaq [1] - The company is currently before a Hearings Panel for non-compliance with Listing Rule 5550(a)(2) and intends to request a stay of the suspension of its securities before February 26, 2025 [2] - The announcement is made in compliance with Nasdaq Listing Rule 5810(b), which mandates prompt disclosure of deficiency notifications [3] Company Overview - Universe Pharmaceuticals INC is headquartered in Ji'an, Jiangxi, China, and specializes in the production and distribution of traditional Chinese medicine derivatives aimed at improving the health of the elderly [4] - The company also distributes biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements from third-party manufacturers, with products sold across 30 provinces in China [4]
Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report